Literature DB >> 7903524

Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.

A Scorilas1, J Yotis, D Gouriotis, A Keramopoulos, K Ampela, T Trangas, M Talieri.   

Abstract

In breast cancer, axillary lymph node invasiveness is the major prognostic factor in predicting relapse and metastasis. Nevertheless, since 30% of node-negative tumours also relapse, it is necessary to develop other independent prognostic factors. Oncogene amplification and overexpression as well as the level of cathepsin-D have been proposed as additional prognostic factors. Recent studies suggest that the acidic lysosomal proteinase cath-D, present in all cells and known to be secreted in breast cancer cells, may be implicated in the process of tumour invasion and metastasis. We have compared the cytosolic cath-D level with the amplification and the overexpression of the oncogenes c-myc and c-erb-b-2 in 62 breast carcinomas (52 primary and 10 metastatic). Using a cut-off level of 60 pmol/mg protein, the status of cath-D showed a positive correlation with c-myc amplification (P = 0.01) or overexpression (P = 0.02). In contrast, no correlation was found between cath-D and c-erb-B-2 amplification or overexpression. Also, no correlation was found between cath-D and established prognostic factors such as node invasiveness, steroid receptors, grade and menopausal status. Nevertheless, a weak correlation was found between cath-D levels and tumour status (P = 0.05). In conclusion, in breast cancer, a high cytosolic cath-D concentration is more frequent in tumours with c-myc amplification and overexpression but is dissociated from c-erb-B-2 amplification or overexpression, suggesting that the determination of cath-D, as well as the latter two markers, will have an additional prognostic value.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903524

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Prognostic evaluation of oestrogen-regulated protein immunoreactivity in ductal invasive (NOS) breast cancer.

Authors:  L Nakopoulou; A C Lazaris; D Baltas; I Giannopoulou; N Kavantzas; A Tzonou
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

2.  C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance.

Authors:  S L Deming; S J Nass; R B Dickson; B J Trock
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

3.  Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.

Authors:  A Scorilas; A Karameris; N Arnogiannaki; A Ardavanis; P Bassilopoulos; T Trangas; M Talieri
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

4.  Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.

Authors:  A Scorilas; T Trangas; J Yotis; C Pateras; M Talieri
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

Review 5.  The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.

Authors:  Cailin O'Connell; Sabrina VandenHeuvel; Aparna Kamat; Shreya Raghavan; Biana Godin
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

6.  A candidate metastasis-associated DNA marker for ductal mammary carcinoma.

Authors:  Patnala Mohan R Achary; Hui Zhao; Zuoheng Fan; Swarna Gogineni; Venkat R Pulijaal; Lawrence Herbst; Panna S Mahadevia; Joan G Jones; Harold P Klinger; Bhadrasain Vikram
Journal:  Breast Cancer Res       Date:  2003-01-30       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.